Reproductive Choices and Attitudes Toward Preimplantation Genetic Testing Among Individuals with Hereditary Cancer Predisposition
Despite low awareness of preimplantation genetic testing for monogenic disorders (PGT-M), a high and stable proportion of individuals with hereditary cancer predisposition express willingness to use PGT-M combined with IVF to prevent transmitting pathogenic variants, underscoring the need for routine reproductive counseling in hereditary cancer care.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body is a massive, bustling city, and your DNA is the master blueprint for how that city is built. Usually, this blueprint is perfect, but sometimes, a single typo gets copied into the instructions. In the world of hereditary cancer, this typo is a "pathogenic variant"—a specific glitch in the genes that act like the city's security guards. When these guards (like the famous BRCA1 and BRCA2 genes) are broken, the city becomes much more vulnerable to attacks, specifically cancer. For people carrying these glitches, life is a constant balancing act: they have to manage their own health risks while also worrying about passing that same broken blueprint down to their children.
This is where science steps in with a high-tech solution called Preimplantation Genetic Testing for Monogenic Disorders, or PGT-M. Think of PGT-M as a super-advanced quality control inspector for a factory. When parents use In Vitro Fertilization (IVF) to create embryos, PGT-M allows doctors to peek at the genetic blueprint of each tiny embryo before it's ever implanted in the womb. If an embryo has the "typo," the factory can choose to skip it and pick a healthy one instead, effectively stopping the cancer risk from being inherited. But here's the big question: Do people who carry these genetic risks actually know about this inspector? And if they do, are they willing to use it? This is the mystery a team of researchers from Poland set out to solve.
The Great Genetic Detective Hunt
In Poland, a team of scientists decided to play detective, but instead of looking for clues in a crime scene, they were looking for answers in the minds of people carrying hereditary cancer risks. They didn't just ask once; they asked twice, conducting two separate surveys—one in 2023 and another in 2026. Why twice? Because in June 2024, the Polish government changed the rules. They started paying for fertility treatments, including IVF, for cancer patients and those at risk. The researchers wanted to see if this new "free ticket" changed how people felt about having healthy babies.
They focused on a specific group: people aged 45 and younger who carry the "typo" in their genes. They asked them a simple but heavy question: "If you could use IVF and PGT-M to make sure your child doesn't inherit your cancer risk, would you do it?"
The Big Surprise: High Hopes, Low Knowledge
The results were a bit like a magic trick where the audience is ready to buy the ticket but doesn't even know the show exists.
First, the researchers found that awareness was surprisingly low. In the 2023 survey, only 28% of people knew what PGT-M was. By 2026, that number actually dipped slightly to 24%. It's as if everyone was standing in a room full of life-saving elevators, but most of them didn't even know the buttons existed.
But here is the twist: despite not knowing about it, almost everyone wanted to use it.
- In 2023, 72% of respondents said they would be willing to use PGT-M + IVF to stop the cancer risk from being passed down.
- In 2026, that number stayed rock-solid at 70%.
This suggests that the barrier isn't that people don't want to protect their future children; the barrier is that they simply haven't been told about the tool that can help. The researchers suggest that the main problem is a lack of information, not a lack of desire.
The Money Question: The "Don't Know" Dilemma
When the researchers asked if people would be willing to pay for this procedure themselves (if the government didn't cover it), the answers got a bit shaky. In the 2026 survey, when they gave people an option to say "I'm not sure," 51% of them chose "Don't know."
This is a crucial clue. It means that while people are emotionally ready to use the technology, they are financially unsure. They aren't saying "No, I won't do it"; they are saying, "I want to, but I don't know if I can afford it." The introduction of government funding in 2024 helped, but the uncertainty remained high, showing that money is still a big worry for these families.
Who Wants It Most?
The researchers also looked at who was most likely to say "Yes." They found one very clear pattern: parenthood status.
- In the 2026 survey, people who did not yet have children were much more eager to use PGT-M (90%) compared to those who already had children (65%).
- This makes sense: if you already have a family, the decision is often in the past. If you are still planning your family, the chance to start fresh with a "clean" genetic slate is incredibly appealing.
Interestingly, having a personal history of cancer didn't make a huge difference in willingness. Whether someone had already fought cancer or was just at risk, their desire to protect their future kids was roughly the same. The only thing that really changed the "Yes" rate was whether they were still in the "planning phase" of their family life.
What This Means for the Future
The study concludes that there is a huge, unmet need for better communication. The people who need this technology the most are the ones who know the least about it. The researchers suggest that doctors and genetic counselors need to stop waiting for patients to ask about PGT-M and start bringing it up as a standard part of the conversation for anyone with hereditary cancer risks.
The paper doesn't claim that this is a solved problem or that everyone will suddenly start using IVF. Instead, it suggests that if we just turn on the lights and tell people about the "quality control inspector" (PGT-M), the willingness to use it is already there, waiting in the wings. The technology is ready, the desire is strong, but the message hasn't fully arrived yet.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.